Filtered By:
Source: European Heart Journal
Education: Study

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 138 results found since Jan 2013.

Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries
Conclusion Ablation may be associated with lower incidence of ischaemic stroke and death in patients with AF. This beneficial finding appears more pronounced in patients with higher thromboembolic risk.
Source: European Heart Journal - August 23, 2016 Category: Cardiology Authors: Friberg, L., Tabrizi, F., Englund, A. Tags: Arrhythmia/electrophysiology Source Type: research

Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke
Conclusion</div>On MDCT, 12.5% of patients showed HALT or reduced leaflet motion, whereas only one of these patients had abnormal valve haemodynamics on echocardiography. Neither HALT nor increased transvalvular gradient were associated with stroke/TIA.</span>
Source: European Heart Journal - March 27, 2017 Category: Cardiology Source Type: research

Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury
Conclusion In the present study, we show that the deletion of the ageing gene p66Shc protects mice from ischaemia/reperfusion brain injury through a blunted production of free radicals. The ROS mediator p66Shc may represent a novel therapeutical target for the treatment of ischaemic stroke.
Source: European Heart Journal - January 6, 2013 Category: Cardiology Authors: Spescha, R. D., Shi, Y., Wegener, S., Keller, S., Weber, B., Wyss, M. M., Lauinger, N., Tabatabai, G., Paneni, F., Cosentino, F., Hock, C., Weller, M., Nitsch, R. M., Luscher, T. F., Camici, G. G. Tags: FASTTRACK BASIC SCIENCE Source Type: research

Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
Conclusions Patients with both AF and renal failure will probably benefit most from having the same treatment as is recommended for other patients with AF, without setting a higher or lower threshold for treatment. Adding additional points for renal failure to the CHADS2 and CHA2DS2-VASc scores did not improve their predictive value.
Source: European Heart Journal - February 2, 2015 Category: Cardiology Authors: Friberg, L., Benson, L., Lip, G. Y. H. Tags: Atrial fibrillation Source Type: research

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number Clinicaltrials.gov: NCT01606995.
Source: European Heart Journal - April 6, 2016 Category: Cardiology Authors: Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., Turpie, A. G. G., the XANTUS Investigators Tags: Atrial fibrillation Source Type: research

Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
ConclusionHigh variability in lipid levels is associated with adverse health-related outcomes. These findings suggest that lipid variability is an important risk factor in the general population.
Source: European Heart Journal - October 21, 2017 Category: Cardiology Source Type: research

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
Source: European Heart Journal - April 27, 2018 Category: Cardiology Source Type: research

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Conclusions Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Dorian, P., Kongnakorn, T., Phatak, H., Rublee, D. A., Kuznik, A., Lanitis, T., Liu, L. Z., Iloeje, U., Hernandez, L., Lip, G. Y. H. Tags: BASIC SCIENCE Source Type: research

Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study
ConclusionAF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.
Source: European Heart Journal - November 18, 2017 Category: Cardiology Source Type: research

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial
ConclusionSerial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF.
Source: European Heart Journal - March 24, 2021 Category: Cardiology Source Type: research

Impact of low stroke volume on mortality in patients with severe aortic stenosis and preserved left ventricular ejection fraction
ConclusionLow flow defined as SVi  <  30 mL/m2 or SV  <  55 mL is an important outcome predictor in severe AS with preserved LVEF under medical and surgical management. Further studies are needed to prospectively test these values for risk stratification and decision making.
Source: European Heart Journal - March 13, 2018 Category: Cardiology Source Type: research

Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
Conclusion  In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS2 score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients.
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research

Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial
Conclusion Renal impairment (CrCl <60 mL/min) doubles the risk of stroke and increased the risk of major bleeding by almost 60% in anticoagulated patients with AF. Renal impairment was additive to stroke risk prediction scores based on a significant NRI, but no significant improvement in discrimination ability (based on c-indexes) for CHA2DS2VASc or CHADS2 was observed.
Source: European Heart Journal - December 7, 2013 Category: Cardiology Authors: Apostolakis, S., Guo, Y., Lane, D. A., Buller, H., Lip, G. Y. H. Tags: Atrial fibrillation Source Type: research

Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes
Conclusion Patients initiating warfarin may be at an increased risk of stroke during the first 30 days of treatment, supporting the biological plausibility of a transient hypercoagulable state at the start of the treatment, although additional studies are needed to confirm these findings.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Azoulay, L., Dell'Aniello, S., Simon, T. A., Renoux, C., Suissa, S. Tags: Atrial fibrillation Source Type: research

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Conclusion Major bleeding was associated with substantially increased risk of death, ischaemic stroke, or MI, especially following ICH, and this risk was similarly elevated regardless of treatment with apixaban or warfarin. These results underscore the importance of preventing bleeding in anti-coagulated patients. Clinical Trials.gov identifier NCT00412984.
Source: European Heart Journal - May 21, 2015 Category: Cardiology Authors: Held, C., Hylek, E. M., Alexander, J. H., Hanna, M., Lopes, R. D., Wojdyla, D. M., Thomas, L., Al-Khalidi, H., Alings, M., Xavier, D., Ansell, J., Goto, S., Ruzyllo, W., Rosenqvist, M., Verheugt, F. W. A., Zhu, J., Granger, C. B., Wallentin, L. Tags: Thrombosis and antithrombotic therapy Source Type: research